中国血液净化

中国血液净化 ›› 2022, Vol. 21 ›› Issue (08): 613-616.doi: 10.3969/j.issn.1671-4091.2022.08.017

• 血管通路 • 上一篇    下一篇

即穿型人工血管FLIXENETM在血管通路中的临床应用

吴 厂  米兰化   施娅雪   刘思洁   鲍雪东   于 敏   胡文平   

  1. 200032 上海，上海中医药大学附属龙华医院血管外科
  • 收稿日期:2022-02-07 修回日期:2022-06-13 出版日期:2022-08-12 发布日期:2022-08-12
  • 通讯作者: 施娅雪 E-mail:drshiyaxue@163.com

Clinical application of early cannulation graft FLIXENE™  for hemodialysis patients 

WU Chang, MI Lan-hua, SHI Ya-xue, LIU Si-jie, BAO Xue-dong, YU Min, HU Wen-ping   

  1. Department of Vascular Surgery, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China
  • Received:2022-02-07 Revised:2022-06-13 Online:2022-08-12 Published:2022-08-12
  • Contact: SHI Ya-xue E-mail:drshiyaxue@163.com

PDF

506

摘要： 目的 总结FLIXENE™(Atrium™，Hudson，NH，USA)即穿型人工血管的临床应用结果。方法 回顾上海中医药大学附属龙华医院血管外科2019年08月～2021年10月建立的48例FLIXENE™即穿型人工血管动静脉内瘘的首次穿刺时间、通畅率及并发症发生率。 结果 48例患者纳入研究，男18例，女30例，平均年龄(60.06±11.93)岁。首次穿刺时间15～336h，中位穿刺时间20(18，22)h。平均随访时间(224.77±151.73)d，随访率100%，血栓2例，狭窄9例，感染2例，无穿刺点血肿、血清肿、假性动脉瘤、窃血综合征发生。3、6和12个月的初级通畅率分别为95.3%、87.4%和63.0%；初级辅助通畅率分别为100%、97.4%和92.2%；次级通畅率均为100%。 结论 FLIXENE™即穿型人工血管术后早期穿刺血液透析是安全可行的。

关键词: 血液透析通路, 即穿型人工血管, 人工血管动静脉瘘

Abstract: Objective  To summarize the preliminary clinical application results of FLIXENE™ (Atrium™, Hudson, NH, USA), an early cannulation artificial vascular graft.  Methods  A total of 48 cases subjected to arteriovenous graft construction using the early cannulation FLIXENE™ vascular graft at the Department of Vascular Surgery, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine from August 2019 to October 2021 were retrospectively analyzed. The first cannulation time, patency rate and incidence of complications were summarized.  Results   There were 18 males and 30 females, with an average age of 60.06±11.93 years. The arteriovenous graft was established in upper limbs (n=40) or in lower limbs (n=8), with the clinical success rate of 100% and without any perioperative complications. The first cannulation time after operation was 15～336h, with the median time of 20 (18, 22) h. The average follow-up time was 224.77±151.73 days, and the follow-up rate was 100%. Complications included thrombus (2 cases), stenosis (9 cases) and infection (2 cases). No hematoma at puncture site, seroma, pseudoaneurysm, or steal syndrome occurred. After the operation for 3, 6 and 12 months, the primary patency rates were 95.3%, 87.4% and 63.0%, respectively, the primary assisted patency rates were 100%, 97.4%, and 92.2% respectively, and the secondary patency rates were 100%.  Conclusions  The early cannulation FLIXENE™ vascular graft is safe and feasible for early cannulation hemodialysis. 

Key words: Hemodialysis access, Early cannulation graft, Arteriovenous graft

中图分类号: